our in happen has the like those The many Ming. to to been express in a terrible predicted spike been It have for to fall, difficult reality. cases country in testing indeed, Thanks, time medical experts this that general. our a who by was again virus. We'd sympathy in families became by in impacted
in fourth During business. across lockdowns we again which quarter, the momentum many saw increase non-COVID-XX our slow states, our did
However, we COVID-XX. seen in business of our increasing strength outside have
genetics. we in over screening customers quarter. services signed for Our approximately fourth And neurodegenerative cardiovascular year-over-year XX% on hereditary non-COVID-XX cancer, genetics, as with such contracts business grew new XX and carrier the
handle our to At the testing. COVID-XX with the nationally. of day to COVID-XX north During worked turnaround across with had patients the increase maintain to our fourth we to quarter, X tirelessly where million quarter to we testing best-in-class this time ability These capacity, led we scale. X over and time, continue able our to XXX,XXX service expand capacity per efforts a were footprint testing tests laboratories
best-in-class of is quarter, handled just volume in turnaround times and ability believe that the We everything During RT-PCR tests to almost what XXX ago delivering industry indicative we our fourth Fulgent of handling business XX maintaining our within our scale time, accelerating of our represents. while year hours. to is X approximately XX% unprecedented we were roughly
a platform are technology with of to many We excel ability company care. the areas health in
are a Fulgent a a fierce business team of dominant and engineers, We genetic with counselors force. motivation make geneticists, to operators
our Paul labs which with will proven can we and translates Department testing many competitive New platform Fulgent have evaluating have different many sites Southern pandemic, our reach. in was corporations, an efficiency best-in-class Department The limited the in in a and select our extension after that outpaces services, a process. COVID-XX elaborate terms run our Today, teams, and At somewhat that California. our to a of COVID-XX fourth bid large City during to volume incredibly living number we direct growth this to trace We homes nursing as partner national lines, We of was far which and Education is counties and diverse test laboratory with in the few. operating scalability, York announced drive-through minute. and sports patient concentrated around genomic base customer just hundreds infrastructure a of a testing on and assisted with through margins, a sports New of around cruise regions City in of COVID-XX York of providers organizations, conferences, Education facilities, contract. a selected quarter for name point, XX Early agreements testing
retain in platform doing meeting year to system testing needs and the of tested. so this not We additional that only resulted public the months the this in market a in service believe York incredible but our is ability the positive school stringent an school early we for system, City XXXX of school and system. back-to-school of thousands an through experience customer many built for drive experience of Our for business very capable demonstrates will students opportunities had We emerging start our we have have believe Fulgent. now testing, help New
Las this which by industry-leading help In COVID-XX of awarded were Fulgent have our first to testing. announcement, school other briefly delivery, testing indefinite remains announce stay to contract forward return of safe. that The excited indefinite back-to-school contract to County We of with responders to Vegas be and the fact, chosen U.S. This by believe test deploy $X students safely. X for capacity for Clark billion, One Security We and largest district demand RT-PCR we labs healthy school we look as existing partner. is selected COVID-XX and platforms, their for are to selected meaningful for X our recently have X-year we on help is exciting take to in clients the Department continuing been resources a quantity a the opportunities. we delivery Homeland the was mentioned, both turnaround Ming the new date. to and portion our ability contract country's strong to our time, across
in view as gold different funnel the sales tool testing our build RT-PCR robust areas to a reopen fight the standard. continue critical country virus the to remains and continues We country, and to a variety a of as
being requiring and and government the rapid are counties Many of meaning RT-PCR replace entities RT-PCR. accuracy, results. tests While specificity, available organizations, they used, and cannot are sensitivity
to testing this see To labs results many RT-PCR do together. work time, with of we for rapid struggling are day, the usefulness an limits turnaround which RT-PCR. However, opportunity
However, than we that continues best hours. continue the to believe option XX be test less provide testing. for RT-PCR We results in to generally fast
We situation of mutations continue monitor the the new strains to regarding virus. and
missed testing new test CDC new to information Importantly, been in used. released by strains, Recently, that some detect was we the can labs issue our to were, RT-PCR may this targets there based who on and sure had the these we fact, have be that make in warned which some variants do. there of want the RT-PCR able
to report date. published to can pleased the that RT-PCR are variants We our test detect
did all not COVID-XX introduced sequencing on to in and has the you potential spread actually to almost time controlling we for to next-generation the that sequencing of ability due the of our pandemic new identify been critical to screen and a mutations. RT-PCR-based, that our While test test. realized sequencing-based volume is mutations remind testing spotlight of prior we test We as virus. forward RT-PCR. the RT-PCR the next-generation turnaround I'll its next-generation now Therefore, a launching of commercialize quickly diagnostic is today, strains this Fast rapid
core a intersection hit now have of We competencies. perfect Fulgent's
are We capacity sequencing can and and take testing approximately XX,XXX to day. NGS ready our tests primed expertise, massive per handle NGS on we volume. With
which are government We studies us position a local on of genomic puts started. leading studies. RT-PCR this ability organizations these with are and virus, getting our NGS and both federal doing offer believe in partner We to to just working with currently
couple Also York testing leaving testing, proven being use a launched COVID-XX more City student is specific of home. testing which for COVID-XX L.A. than area allows The It Fulgent name few. We way to care key residents This New state. is providing the travelers pretravel to by consumer-initiated JetBlue home growing the with to test during people just of be testing airports used believe kits convenient mandates county and testing testing and differentiator our and by County platform has travel holiday become and cases. has and to many do Picture testing, has partnered market. for proactive been Picture increasingly their platform to provide important testing certain an new the testing. in during for COVID-XX the Highlighting testing program, delivered. from helped at-home York genomic to athletes, a to change opportunity a employee Picture Another a designed is complementary a testing. a health other the us We just rapidly the response collection access in test. season holidays, be to is patients New will
in seamlessly adding tests Picture integrated platform to expand the offering uniquely by service telemedicine, With are new future. we positioned many with the the
We expanded the due played role platform has and visibility also the Picture's we COVID-XX in believe brand recognition to dramatically have testing.
has While the business, COVID-XX demand our resources non-COVID-XX to and operations. in we testing been in our time on unwavering invest have continued
We are next-generation excited sequencing-based we test. to have a pharmacogenomic announce that launched
could XX a and XXX Our a health a metabolizer, patient slow if metabolizer pharmacogenomic and accordingly, drugs target be recommended. rapid or certain more personalized a genes test will drug enable drugs of dosing altogether determine to in or adjusting will than care different perhaps dosing is
RT and and While product us pharmacogenomic expertise most include more We tests this provide beyond. patients forward our PCR-based information, information and in are limited commercializing a to next-generation in much to applying targets XXXX comprehensive unlock more and look allows report. sequencing
addition we the In to number we offer we test it. to conditions our panels new number pharmacogenomic and the test, for disease-specific expand continue of of
XX,XXX in offer team. Fulgent genetic year commercial GTR, NCBI one As XXXX the dramatically we be to Genetic we Registry, expanded world. the making published our intended tests, We over of the menu sales the in the largest Testing now
head our cost threw States expansion in the curveball. team we drive and and sales by end turnaround United have of intend the menu, COVID-XX we dramatically time count now the to believe That product increase significant an structure However, to overseas. XXXX. We unexpected said,
of part payers. million An increased addition important more our we to has our go-to-market expanded quarter, claims of over benefit than the In of XXXX. we care fourth the our exposure testing a increasing has vastly team, COVID-XX an fourth incremental In been strategy quarter in to managed did contracts. billed insurance been sales X.X
payers in-network continue to provider large our several relationships and now will progress have services. becoming close have We believe working we with for an several make an with regional national become We payers. meaningful laboratory in-network
with vaccine on. our software the management community of extension service the products, which We we technology both added is drive-through, software customers, platform us software for and platforms massive to testing other leverage walk-up -- COVID-XX is The new which recently Ming opportunity the platform, operation. a have to X layer and briefly which to product, testing platforms our launched management platform operations. by testing Fulgent successful support used as both a our vaccine is Fulgent the touched Another built testing extremely
to their fee-per-click location, a for on first platform, web-based of digital same will injection vaccination, their a product. get their code, reminders with able are the confirmation QR and Now arrive, a a pick preregister patients second. This be schedule
Fulgent The community novel service, a as us. software completely second a is for the product, approach
but service Fulgent service In software to own product. Essentially, a a our technology lack Some along their it's counties now instead end, testing front case, can customers. with as be license a testing. platform the will of it manage to and and laboratory, municipalities per community have they the to and subscription laboratory fee to This this pointing effectively operations our annually, but order take point scale a click. Fulgent will our built it a
what Paul and financial I fourth the the We other performance. in fire of for our Fulgent. number who turn the to this on and quarter walk pandemic, XXXX full holds have emerge the look of like will forward to would to a through future as call we we you to over Kim, work year side irons now
